A Phase 2 interventional study of IV Gamunex 10% in IgG Deficiency and Infections, sponsored by The Center for Rheumatic Disease, Allergy, & Immunology. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-01-01.
Sponsored by The Center for Rheumatic Disease, Allergy, & Immunology · Phase 2, Interventional, and Treatment
*10 consenting adults (18 or older) will receive IgIV (Gamunex 10%) monthly at a dose of 400mg/kg body weight IV at 3ml/minute. Comprehensive labs will be monitored at each visit, as well as clinical eval, plus patients will complete a questionnaire each time. There is also a 3 month follow-up visit after completion of therapy. Specific xrays will be done at the beginning and with the last treatment.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 10 is below the median of 120 across 4,200 interventional studies indexed under Infections.
Browse Infections studies →The Center for Rheumatic Disease, Allergy, & Immunology is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Lab values ck'ed baseline and with each treatment, and 15 mo. visit
Xray of Chest and sinus baseline and on 12th and last treatment
Clinical assessment baseline, every treatment, and 15 mo.
Patient questionnaires completed by patients, baseline, prior to each treatment, and at 15 month vist.
This study is completed, as verified in Dec 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Center for Rheumatic Disease, Allergy, & Immunology